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ABSTRACT

Objective Sarcomeric gene mutation carriers without
overt left ventricular hypertrophy (G+/LVH−) can harbour
subclinical changes in cardiovascular structure and
function that precede the development of hypertrophic
To cite: Ho JE, Shi L, Day SM, et cardiomyopathy (HCM). We sought to investigate if
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collagen metabolism among G+/LVH− individuals,
stress and fibrosis in
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further insights into the underlying biology of HCM.
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Methods We studied 76 individuals with overt HCM,
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50 G+/LVH− individuals and 41 genotype-negative
related controls enrolled in a cross-sectional, multicentre
observational study (HCMNet). Biomarkers of cardiac
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and fibrosis (carboxy-terminal propeptide of procollagen
type I; C-terminal telopeptide of type I collagen; galectin-3;
periostin) were measured.
Results Individuals with overt HCM had elevated NTproBNP and hsTnI compared with G+/LVH− subjects and
controls at rest, along with an exaggerated increase in
NT-proBNP and hsTnI in response to exercise. We found
no detectable differences in resting or exercise-provoked
biomarker profiles of cardiovascular stress and fibrosis
among G+/LVH− individuals compared with healthy
controls despite subtle echocardiographic differences in
cardiac structure and function.
Conclusion Dynamic exercise testing exaggerated resting
differences in natriuretic peptides and troponin elevations
among individuals with overt HCM. In contrast, we found
no differences in biomarker profiles of cardiovascular
stress and fibrosis among G+/LVH− individuals compared
with controls even after maximal exercise provocation. Our
findings highlight the need for continued investigation into
early phenotypes of sarcomeric gene mutations and the
evolution of HCM.
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Introduction
Hypertrophic
cardiomyopathy
(HCM)
is frequently caused by sarcomeric gene
mutations.1 Due to the autosomal dominant nature of inheritance, each immediate relative of an affected individual has a

Key questions
What is already known about this subject?
Sarcomeric gene mutation carriers without overt
left ventricular hypertrophy (G+/LVH−) can harbour
subclinical changes in cardiovascular structure and
function that precede the development of hypertrophic
cardiomyopathy (HCM).

What does this study add?
Despite subtle subclinical changes in cardiovascular
structure and function on echocardiography, we found
no differences in biomarker profiles of cardiovascular
stress and fibrosis among G+/LVH− individuals
compared with controls even after maximal exercise
provocation.

How might this impact on clinical practice?
The potential plasticity of early phenotypic
manifestations in genotype-positive individuals may
present future opportunities for prevention in the
preclinical phase of the disease; however, our findings
highlight the need for continued investigation into early
phenotypes of sarcomeric gene mutations and the
evolution of HCM.

50% chance of carrying the disease-causing
mutation and potentially developing HCM.
Therefore, current guidelines recommend
longitudinal screening of first-degree family
members of patients with this diagnosis.2
Most frequently serial clinical evaluation is
performed; however, genetic testing provides
the opportunity for more definitive identification of at-risk relatives, and its use has
become more widespread. This has resulted
in a growing population of genotype-positive individuals without overt left ventricular
hypertrophy (LVH), and the unique opportunity to study preclinical phenotypes prior
to the development of overt clinical manifestations of HCM.3 Prior studies suggest that
adverse cardiovascular effects of pathogenic
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sarcomeric gene mutations may be at play long before
the diagnostic clinical phenotype, LVH, is manifest.
These findings include abnormal myocardial energetics,
impaired left ventricular (LV) relaxation,4 altered intracellular calcium handling5 and transcriptional upregulation of fibrotic pathways.6 7 The potential plasticity of early
phenotypic manifestations is supported by animal models
and clinical data, suggesting that treatment of mutation
carriers with diltiazem may improve cardiac remodelling
if administered in the preclinical phase of the disease.5 8
A number of previous imaging studies focused on genotype-positive/LVH-negative (G+/LVH−) individuals have
demonstrated abnormalities in cardiac structure and
function.4 9–11 In contrast, there are few studies of circulating biomarkers of cardiovascular stress and collagen
metabolism in G+/LVH− individuals with conflicting
results to date.12 13 Therefore in this study, we sought
to examine specific biomarkers reflecting cardiac stress
(N-terminal pro-B-type natriuretic peptide, NT-proBNP;
high-sensitivity troponin I, hsTnI; soluble ST2) and
fibrosis (carboxy-terminal propeptide of procollagen type
I, PICP; C-terminal telopeptide of type I collagen, CITP;
galectin-3; periostin) in a well-characterised genotyped
population, to attempt to examine potential pathways
underlying subclinical disease in G+/LVH− individuals.
Lastly, we explored the potential for exercise stress to
unmask and provoke latent phenotypic traits. Cardiopulmonary responses to exercise are predictors of
outcome among patients with HCM.14 Exercise can
also enhance detection of cardiovascular dysfunction,
including abnormal LV strain and twisting reserve in
HCM.15 Among general cardiology patients referred for
clinical exercise testing, transient stress-induced ischaemia can be detected via ultrasensitive troponin assays.16
Exercise has not been examined as a means to uncover
subclinical disease in G+/LVH− individuals. Examining
such provoked phenotypes is of particular interest to
further explore mechanisms underlying the formation
of myocardial fibrosis in HCM, a key feature of clinically
overt HCM.
Increased replacement and interstitial fibrosis are
histopathological hallmarks of disease, and the majority
of adults with HCM have demonstrable late gadolinium
enhancement on cardiac MRI (CMR).17 Although the
processes driving scar formation have not been rigorously
characterised, it is generally considered to be a secondary
consequence of ischaemic and haemodynamic stressors
associated with HCM. However, both animal models and
studies on preclinical human populations have suggested
that profibrotic pathways are activated early in the pathogenesis of HCM, prior to the development of LVH.12 A
potential hypothesis is that the presence of a sarcomeric
gene mutation may make the myocyte more susceptible
to injury. Although this susceptibility may not be detectable at rest, it may be unmasked by stress. We therefore
sought to examine provoked phenotypes, as reflected by
circulating biomarker levels measured after physiological stress, to investigate whether exercise testing might
2

unmask subclinical phenotypes and a predisposition to
myocardial injury among sarcomeric gene mutation
carriers.
Methods
Study sample
Participants with overt HCM (G+/LVH+), mutation
carriers without LVH (G+/LVH−) and healthy genotype-negative members of families with known mutations
were enrolled in a cross-sectional, multicentre observational study (HCMNet) based at 11 HCM specialty centres
in the USA (see online supplementary table 1). Genotype-positive individuals >5 years of age were included if
sarcomeric gene mutations were deemed pathogenic or
likely pathogenic based on segregation, conservation and
absence from control populations according to standard
criteria, and reassessed at the time of data analysis.18 All
genetic testing was performed at Clinical Laboratory
Improvement Amendments (CLIA_-approved facilities.
Individuals with overt HCM were defined as sarcomeric
gene mutation carriers with LV wall thickness ≥12 mm
in adults >18 years or z-score of ≥3 in subjects under 18
years of age as previously described.12 Participants were
deemed G+/LVH− if they were mutation carriers with a
normal LV wall thickness (defined as maximal thickness
under the limits above). Healthy genotype-negative relatives with normal LV wall thickness by echocardiogram
comprised the control population. Participants with
known hypertension, cardiovascular disease other than
HCM, prior cardiac surgery or alcohol septal ablation, or
comorbid conditions potentially altering collagen turnover (cirrhosis, liver, pulmonary, renal fibrosis, inflammatory states) were excluded from the study. Individuals >40
years of age were excluded from G+/LVH− and control
groups. All participants provided informed consent.
Study procedures
Participants underwent comprehensive medical and family
history, physical exam, and symptom-limited treadmill exercise tolerance testing using a standard Bruce protocol.
Transthoracic echocardiography was performed,
including two-dimensional, spectral, colour and tissue
Doppler interrogation. Left atrial (LA), LV dimensions
and standard parameters of diastolic function, including
spectral Doppler transmitral early (E) and late (A)
velocities and E wave deceleration time, were measured
according to published guidelines.19 Tissue Doppler
velocities of the lateral, septal, anterior and inferior mitral
annulus were measured, and global e' velocity calculated
as the average of these four values.11 Studies were analysed at a central core laboratory blinded to clinical and
genotype status. Echocardiographic measurements were
converted to z-scores (number of SD from the normal
mean value relative to age or body surface area) due to
the wide age range in our study cohort.20
CMR with gadolinium enhancement was performed in
available subjects without contraindications. ECG-gated
Ho JE, et al. Open Heart 2017;4:e000615. doi:10.1136/openhrt-2017-000615
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images were obtained during breath-hold using 1.5T
or 3T systems using cine steady-state free precession
imaging for LV function and mass.21 Late gadolinium
enhancement was determined as previously described,
and quantified as a percentage of the total LV mass.11 All
CMR analyses were performed using QMass MR (V.7.4,
Medis, Leiden, The Netherlands) by a core laboratory
blinded to clinical and genotype status.
Biomarker assessment
Venous blood samples were obtained at rest, immediately
after peak exercise and 4 hours post exercise, and serum
and K3-EDTA plasma samples processed and frozen at
−80°C for further analysis by the biomarker core laboratories (Brigham and Women’s Hospital, Boston, Massachusetts, USA, for NT-proBNP, hsTnI, soluble ST2 and
galectin-3; University of Navarra, Pamplona, Spain, for
PICP, CITP, periostin and bone alkaline phosphatase
(BAP)). Biomarkers were assayed using commercially
available reagents by personnel blinded to clinical status
and genotype. For assay details and characteristics, please
see online supplementary methods.
Statistical analysis
Of 193 individuals enrolled in HCMNet, 15 were
excluded due to genetic variants deemed to be of
uncertain significance at the time of data analysis, and
11 individuals were excluded due to missing baseline
NT-proBNP measures. Baseline characteristics were
summarised by the three study groups (G+/LVH+, G+/
LVH− and controls) and compared using analysis of
variance (ANOVA), and pairwise comparisons assessed
using two-sample t-tests. Bonferroni-corrected p values
of less than 0.017 were considered statistically significant.
Biomarkers were log-transformed due to skewed distributions, and values below the detectable threshold were
set to the lower detection limit (n=11 for NT-proBNP).
The ratio of PICP/CITP was examined as an integrated
measure of collagen type I synthesis and degradation.22
The ratio of PICP to BAP was examined to account
for bone collagen turnover.23 NT-proBNP, soluble ST2
(sST2), hsTnI and galectin-3 concentrations before
and after exercise testing were assessed, and change in
biomarker concentrations compared between groups.
Differences between groups were assessed using generalised estimating equations (GEEs) adjusted for age, sex
and familial correlation using an exchangeable correlation structure.
In exploratory analyses, we compared biomarkers
before and after exercise between MYH7 and MYBPC3
mutation carriers, as well as between thick filament
(MYBPC3, MYH7, MYL2, MYL3) and thin filament mutation carriers (ACTC, TTNT2, TNNI3, TPM1). Correlations
between biomarkers and measures of cardiac structure
and function on echocardiography and CMR and exercise testing were assessed using GEE after adjusting for
age, sex and family correlation. For correlation analyses,
we accounted for six biomarkers tested, and deemed a
Ho JE, et al. Open Heart 2017;4:e000615. doi:10.1136/openhrt-2017-000615

p value of 0.01 as significant. All analyses were conducted
using the Statistical Analysis System V.9.3.
Results
A total of 167 genotyped individuals were enrolled in
this study, including 76 with overt HCM (G+/LVH+), 50
genotype-positive, LVH-negative individuals (G+/LVH−)
and 41 genotype-negative controls. Individuals with overt
HCM were older than G+/LVH− individuals (27±14 vs
20±11 years, p<0.05; table 1). The majority of individuals with overt HCM were asymptomatic, with 83% New
York Heart Association class I symptoms and 33% taking
beta-blockers. Genotyping revealed the majority of mutations were present in MYH7 and MYBPC3 in both G+/
LVH+ and G+/LVH− individuals.
On echocardiography, those with overt HCM had
larger LA dimensions, smaller LV dimensions, greater LV
wall thickness and lower mitral annular tissue Doppler
velocities compared with the G+/LVH− and genotype-negative groups (table 1). In contrast to overt HCM,
differences in LA size, LV dimensions and tissue Doppler
were less pronounced between G+/LVH− individuals
and genotype-negative controls. Among a subset of individuals (n=96) who underwent CMR, late gadolinium
enhancement was ascertained in 39 G+/LVH+, 29 G+/
LVH− and 23 controls. Among this group, 44% of the
G+/LVH+ group and none in the G+/LVH− group had
evidence of late gadolinium enhancement.
Baseline biomarker characterisation of overt and preclinical
HCM
Individuals with overt HCM had higher baseline
NT-proBNP (median 137 pg/mL (25th–75th percentile
60, 569)) compared with G+/LVH− and controls (45 pg/
mL (20, 72) and 32 pg/mL (15, 51), respectively, adjusted
p for each pairwise comparison <0.0001; table 2). Similarly, those with overt HCM had higher baseline hsTnI
concentrations (6.3 (3.2, 11.7)) compared with G+/LVH−
and control groups (1.9 (1.3, 5.0), p=0.008; and 1.4 (0.9,
2.4) ng/mL, p=0.03, respectively). There were no significant differences in NT-proBNP or hsTnI between G+/
LVH− and controls. Further, there were no significant
between-group differences detected for soluble ST2, or
biomarkers of fibrosis, including galectin-3, PICP, CITP,
PICP/CITP ratio, BAP, PICP/BAP ratio and periostin (p
for ANOVA >0.05 for all; table 2).
In exploratory analyses, there were no biomarker
differences when stratified based on underlying genotype (MYH7 (n=46) vs MYBPC3 (n=65) gene mutations)
(see online supplementary table 2). Similarly, there were
no significant differences in biomarkers between individuals with thick filament (MYBPC3, MYH7, MYL2, MYL3)
compared with thin filament mutations (ACTC, TTNT2,
TNNI3, TPM1; see online supplementary table 3).
Exercise effects on biomarkers of cardiovascular stress
Exercise provocation enhanced differences in NT-proBNP
between the G+/LVH+ group compared with G+/
3
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Table 1 Baseline characteristics by study group (n=167)
Overt HCM (n=76)
Clinical characteristics
Age, years
Women, n (%)

25 (33)*†

Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Height, cm
Weight, kg
Body surface area, kg/m

27 (14)*†

2

115 (15)
67 (9)

Preclinical HCM (n=50)
20 (11)

Control (n=41)
17 (8)

28 (56)

24 (56)

0.007

113 (13)

0.71

68 (9)

66 (9)

0.55

168 (18)*†

162 (14)

159 (18)

0.012

72 (24)*†

62 (18)

58 (21)

0.002

1.83 (0.42)*†

1.67 (0.32)

1.59 (0.39)

0.003
–

 Class I

63 (83)

50 (100)

41 (100)

 Class II

9 (12)

0 (0)

0 (0)

 Class III

2 (3)

0 (0)

0 (0)

 Class IV

2 (3)

0 (0)

0 (0)

Medication use, n (%)

–
25 (33)

0 (0)

0 (0)

 Calcium channel blocker

9 (12)

1 (2)

0 (0)

  ACE inhibitor/ARB

4 (5)

0 (0)

0 (0)

  MYH7

26 (34)

20 (40)

  MYBPC3

39 (51)

26 (52)

7 (9)

1 (2)

Genetic background, n (%)

  TNNT2

0.0002

113 (13)

NYHA class, n (%)

  Beta-blocker

p for ANOVA

0.51

Imaging characteristics
3.7 (0.9)*†

3.0 (0.5)*

2.8 (0.5)

<0.0001

LV end-diastolic dimension, z-score

Left atrial diameter, cm

−2.6 (1.6)*†

−1.8 (1.2)*

−1.2 (1.3)

<0.0001

LV end-systolic dimension, z-score

−2.5 (2.0)*†

−1.6 (1.2)*

−0.7 (1.4)

<0.0001

LV wall thickness, z-score

10.0 (6.7)*†

1.4 (1.3)

1.1 (1.3)

<0.0001

67 (10)*

67 (8)*

63 (8)

0.048

LV ejection fraction, %
E/A ratio

1.6 (0.5)*†

2.0 (0.6)

2.0 (0.5)

<0.0001

Deceleration time, ms

214 (67)*†

184 (43)

182 (44)

0.003

Mitral valve global e', cm/s

11.3 (3.6)*†

15.2 (1.9)*

16.2 (2.3)

<0.0001

9.6 (1.8)

0.003

Mitral valve global s', cm/s

9.0 (2.0)†

10.3 (1.9)

CMR LGE present, n (%)

18 (46)

–

–

–

CMR LGE, % LV mass

5.9 (7.6)

NA

NA

–

Exercise testing
Duration, min
Peak MET, mL O2/kg/min

11.6 (3.0)
13.1 (3.8)

12.2 (2.2)
14.3 (2.6)

11.9 (3.0)
14.3 (3.2)

0.48
0.08

Values are mean (SD) unless otherwise indicated.
Cardiac MRI performed on a subset of n=41 overt HCM, n=32 preclinical HCM and n=23 controls, of whom LGE was assessed in n=39, 29
and 23 individuals.
*Indicates p<0.05 versus control.
†Indicates p<0.05 versus preclinical HCM.
ANOVA, analysis of variance; ARB, angiotensin receptor blocker; CMR, cardiac MRI; HCM, hypertrophic cardiomyopathy; LGE, late
gadolinium enhancement; LV, left ventricular; MET, metabolic equivalent; NA, not applicable; NYHA, New York Heart Association; MYH7,
myosin heavy chain 7; MYBPC3, myosin binding protein C; TNNT2, troponin T2.

LVH− and controls. Specifically, NT-proBNP increased by
37 pg/mL (27%) in the G+/LVH+ group after exercise,
compared with a 9 pg/mL increase (20%) in the G+/
4

LVH− group, and 8 pg/mL increase (25%) in the control
groups (p<0.0001 for both comparisons; table 2). Similarly, hsTnI increased by 1.5 ng/mL (24%) 4 hours after
Ho JE, et al. Open Heart 2017;4:e000615. doi:10.1136/openhrt-2017-000615
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Table 2 Baseline and postexercise cardiovascular biomarkers by study group
Overt HCM (n=76)

Preclinical HCM (n=50) Control (n=41)

Baseline biomarkers, median (25th–75th percentile)
137 (60, 569)*†
 NT-proBNP, pg/mL
 High-sensitivity troponin, ng/mL

6.3 (3.2, 11.7)*†

0.0005

1.9 (1.3, 5.0)

1.4 (0.9, 2.4)

0.03

22.8 (18.5, 31.3)

0.83

11.4 (10.2, 12.8)

11.5 (9.7, 12.9)

0.97

102.5 (84.5, 144.8)

114.9 (73.3, 184.9)

0.94

6.1 (3.5, 11.5)

5.2 (3.3, 11.4)

0.32

18.7 (12.6, 32.0)

15.8 (10.3, 26.1)

17.6 (13.8, 26.5)

0.09

1.5 (1.1, 2.4)

1.4 (1.1, 2.6)

1.3 (1.0, 1.9)

0.72

29.2 (21.5, 37.3)

 Galectin-3, pg/mL

11.1 (9.7, 13.4)

 PICP, μg/L

95.4 (67.6, 141.2)

 CITP, μg/L

4.4 (3.1, 10.0)

 BAP, U/L

32 (15, 51)

26.5 (20.0, 35.5)

 Soluble ST2, ng/mL

 PICP/CITP ratio

45 (20, 72)

p for ANOVA

 PICP/BAP ratio

57.1 (38.8, 114.6)

68.9 (37.9, 107.8)

 Periostin

70.5 (56, 93.5)

73.5 (61, 95)

87.7 (50.9, 129.0)
73 (60, 92)

0.81
0.99

Immediate or 4-hour postexercise biomarkers, median (25th–75th percentile)
 NT-proBNP, pg/mL
 Change in NT-proBNP, pg/mL

199 (84, 775)*†

54 (27, 93)

41 (23, 77)

0.0004

37 (14, 133)*†

9 (5, 18)

8 (3, 25)

0.0004

 % Change in NT-proBNP (%)

27 (15, 43)

27 (13, 40)

38 (13, 70)

0.08

 4-Hour hsTnI, ng/mL

8.9 (5.4, 18.0)*

2.6 (1.4, 7.2)

2.0 (1.3, 3.8)

0.03

 Change in hsTnI, ng/mL

1.5 (−0.4, 4.5)

0.3 (−0.2, 1.3)

0.4 (−0.2, 1.0)

0.43

 % Change in hsTnI (%)
 4-Hour soluble ST2, ng/mL
 Change in sST2, ng/mL
 % Change in sST2 (%)

28 (−4, 67)

17 (−11, 58)

28 (−10, 76)

0.25

36.1 (26.1, 42.8)

34.5 (25.7, 45.6)

31.5 (24.3, 37.8)

0.66

4.5 (0.5, 9.8)
17 (1, 36)

7.9 (2.4, 10.9)
28 (10, 42)

6.3 (2.0, 11.0)
19 (13, 41)

0.68
0.99

*Indicates p<0.05 versus control.
†Indicates p<0.05 versus preclinical HCM in generalised estimating equations regression analyses accounting for age, sex and familial
correlation.
ANOVA, analysis of variance; BAP, bone alkaline phosphatase; CITP, C-terminal telopeptide of type I collagen; HCM, hypertrophic
cardiomyopathy; hsTnI, high-sensitivity troponin I; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PICP, propeptide of procollagen
type I; sST2, soluble ST2.

exercise in the G+/LVH+ group, compared with 0.3 ng/
mL (16%) in the G+/LVH− and 0.4 ng/mL (29%) in
the control groups, although between-group differences
were statistically not significant (p for ANOVA 0.22).
Lastly, soluble ST2 concentrations increased in all three
groups 4 hours after exercise with no significant betweengroup differences (p for ANOVA 0.97).
Biomarkers correlate with cardiac structure and function in
genotype-positive individuals
Among genotype-positive individuals, NT-proBNP was
significantly correlated with measures of cardiac structure and function (figure 1). Specifica lly, NT-proBNP
was correlated with greater LA diameter, greater LV wall
thickness, lower mitral e' tissue Doppler velocity and
greater late gadolinium enhancement by CMR (p<0.001
for all analyses adjusted for age, sex and familial correlation; table 3).
Similarly, hsTnI was correlated with larger LA diameter, greater LV wall thickness and lower mitral e' velocity
(p<0.0001 for all). We did not find significant associations
of soluble ST2 and cardiac structure or function. Lastly,
galectin-3 concentrations were associated with lower E/A
Ho JE, et al. Open Heart 2017;4:e000615. doi:10.1136/openhrt-2017-000615

ratio (p=0.001), but no other associations with cardiac
measures were observed (table 3).
Discussion
Among a young population of sarcomeric gene mutation
carriers with overt HCM, mutation carriers without LVH
and healthy genotype-negative members of families with
known mutations, we found that both NT-proBNP and
hsTnI were elevated in those with overt HCM. This difference was further enhanced by dynamic exercise testing,
with an exaggerated increase in natriuretic peptides in
response to exercise among individuals with overt HCM.
Interestingly, despite detectable echocardiographic
differences in cardiac structure and function among
mutation carriers and genotype-negative controls, we
found no significant difference in resting or exercise-provoked biomarker profiles of cardiovascular stress and
fibrosis among preclinical mutation carriers compared
with healthy controls.
The growing use of genetic testing has allowed identification of an intriguing population of individuals who
carry disease-causing sarcomeric gene mutations at a
5
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Figure 1 Association of biomarker quartiles and
echocardiographic traits. Panel A shows left atrial diameter
across NT-proBNP and hsTnI quartiles; panel B shows left
ventricular wall thickness; and panel C shows tissue Doppler
velocity for global mitral annular velocity. p for trend <0.0001
for all traits shown. hsTnI, high-sensitivity troponin I; LA, left
atrial; LV, left ventricular; NT-proBNP, N-terminal pro-B-type
natriuretic peptide.

stage when LVH or diagnostic clinical manifestations of
HCM are absent.24 Although the penetrance of sarcomeric gene mutations may be variable or incomplete,
this preclinical population is at high risk for developing
HCM and therefore provides a unique opportunity
to examine early phenotypes that may herald adverse
cardiovascular remodelling that ultimately leads to
clinical disease. Previous studies have demonstrated
subclinical abnormalities in diastolic function, myocardial deformation and other structural abnormalities
among mutation carriers.10 25 26 In addition to differences
detected on imaging modalities, early transcriptional
changes and altered myocardial energetics may also be
6

at play.6 7 Notably, few studies have examined circulating
biomarkers in this preclinical population.
Two smaller previous studies have shown no difference
in resting NT-proBNP concentrations among mutation
carriers compared with unaffected relatives.11 13 We now
extend these results to include biomarker profiles obtained
during exercise testing as a dynamic assessment of cardiovascular response to stress, and demonstrate that even with
provocation, NT-proBNP does not differ among mutation
carriers and unaffected relatives. In contrast, baseline differences in NT-proBNP among individuals with overt HCM are
further unmasked with exercise.
Second, we present a broader range of biomarkers of
cardiovascular stress and fibrosis among preclinical mutation carriers compared with prior studies. Prior studies
have demonstrated mixed results with regard to markers
of collagen metabolism among patients with HCM.27–29
In a single-centre study, we previously observed a higher
concentration of PICP among mutation carriers.12 This was
not replicated in the current multicentre cohort, and may
be due to age differences in the control group. It may be
that older samples with more advanced disease may display
different biomarker profiles, including markers of neurohormonal activation, myocyte injury and cardiac fibrosis. Of
note, PICP concentrations were quite high in our control
group. This may be in part due to the young age of mutation-negative controls (mean age 17 years), raising the possibility of bone turnover and growth during adolescence as
potential confounder of PICP concentrations that is not
fully accounted for by assessing BAP.30 In addition, physical exercise is a known source of bone turnover, and it has
been shown in adolescent males (aged 15–17 years) that
PICP increases with chronic aerobic/endurance training,31
which may have influenced our study results. Lastly, given
that apparently healthy controls were still selected from
families with HCM participants, there may be other potential confounding factors at play, including possible unrecognised genetic and familial determinants of circulating
PICP.32
Galectin-3 is a potential mediator of cardiac fibrosis
in experimental studies,33 and also reflects the degree
of cardiac fibrosis in non-ischaemic cardiomyopathy as
assessed by late gadolinium enhancement on CMR.34
Circulating galectin-3 can be elevated years prior to clinically apparent heart failure35; thus, we sought to investigate whether galectin-3 may be elevated early in the
course of HCM. We did not find a difference in galectin-3
among patients with HCM compared with genotype-negative related controls. These findings contrast with a prior
case–control study showing that galectin-3 was higher
in 40 patients with HCM compared with 35 unrelated
healthy controls.36 This discrepancy may be due to differences in age, as our sample was over 20 years younger
on average, compared with the prior case–control study.
It is also important to note that galectin-3 levels are in
part genetically determined,37 which may blunt potential differences among related individuals such as in our
study. Among genotype-positive individuals, galectin-3
Ho JE, et al. Open Heart 2017;4:e000615. doi:10.1136/openhrt-2017-000615
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Table 3 Correlations between biomarkers and imaging characteristics among genotype-positive individuals
NT-proBNP

LA diameter

hsTnI

Beta (SE)

p Value

0.67(0.12)

<0.0001

Beta (SE)
0.64 (0.11)

Soluble ST2
p Value
<0.0001

Beta (SE)
0.14 (0.12)

Galectin-3

Periostin

p Value Beta (SE)

p Value Beta (SE)

0.22

0.09

0.22 (0.13)

0.11 (0.12)

p Value
0.35

LVEDD z-score

−0.14 (0.06)

0.018

−0.01 (0.06)

0.91

0.01 (0.05)

0.79

0.03 (0.07)

0.61

0.04 (0.06)

0.58

LVESD z-score

−0.12 (0.06)

0.033

0.02 (0.05)

0.72

0.02 (0.05)

0.68

0.04 (0.06)

0.49

0.02 (0.05)

0.67

LVWT z-score

0.11 (0.01)

<0.0001

0.06 (0.01)

<0.0001

−0.01 (0.01)

0.59

0.01 (0.02)

0.63

0.02 (0.01)

0.15

LVEF, %

0.01 (0.01)

0.20

−0.002 (0.01)

0.84

−0.002 (0.01)

0.79

−0.02 (0.01)

0.09

0.001 (0.01)

0.96

E/A ratio

−0.19 (0.14)

0.19

−0.34 (0.15)

0.03

−0.10 (0.13)

0.45

−0.49 (0.14)

0.001

0.03 (0.16)

0.84

0.23

−0.002 (0.002)

0.21

Deceleration time

0.0004 (0.002)

0.81

0.004 (0.002)

0.02

0.002 (0.001)

0.06

0.002 (0.002)

Global e' z-score

−0.21(0.02)

<0.0001

−0.16 (0.02)

<0.0001

0.01 (0.03)

0.65

−0.05 (0.03)

0.15

−0.03 (0.03)

0.21

Global s' z-score

−0.20 (0.05)

0.0002

−0.13 (0.04)

0.003

0.08 (0.03)

0.02

−0.04 (0.05)

0.42

−0.07 (0.04)

0.10

0.07 (0.01)

<0.0001

0.02 (0.01)

0.02

0.02 (0.01)

0.03

0.01 (0.01)

0.24

0.07 (0.01)

<0.001

CMR LGE, %
Exercise duration

−0.13 (0.03)

0.0001

−0.04 (0.03)

0.15

0.01 (0.03)

0.66

−0.03 (0.03)

0.31

−0.03 (0.03)

0.40

Peak MET

−0.12 (0.02)

<0.0001

−0.05 (0.03)

0.07

0.02 (0.02)

0.46

−0.05 (0.03)

0.12

−0.03 (0.03)

0.19

Beta coefficient represents the change in imaging characteristic per 1 SD increase in log-transformed biomarker, after adjustment for age, sex and
familial correlation.
CMR, cardiac MRI; hsTnI, high-sensitivity troponin I; LA, left atrial; LGE, late gadolinium enhancement; LVEDD, left ventricular end-diastolic dimension;
LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; LVWT, left ventricular wall thickness; MET, metabolic equivalent;
NT-proBNP, N-terminal pro-B-type natriuretic peptide.

was negatively correlated with E/A ratio, although we
found no association with other measures of diastolic
function or late gadolinium enhancement by CMR.
Lastly, we examined soluble ST2, an interleukin-1
receptor family member that is upregulated in cardiomyocytes in response to stress.38 Although patients with
HCM had numerically higher soluble ST2 concentrations, there was no statistical difference among groups.
In contrast to the paucity of studies on biomarkers
in mutation carriers, numerous previous studies have
examined cardiovascular biomarkers among patients
with overt HCM. Our findings are congruent with others
showing elevated natriuretic peptide and troponin
concentrations in HCM, which in turn predict functional
capacity and clinical prognosis among this patient population.39–42 Among genotype-positive individuals, we also
found that NT-proBNP and hsTnI were correlated with
cardiac remodelling, including LA size, LV wall thickness,
diastolic function as assessed by tissue Doppler mitral
annular e' velocity, and regional fibrosis based on late
gadolinium enhancement, similar to prior studies.39 43 44
Several additional limitations deserve mention. The
utility of circulating biomarkers among mutation carriers
without LVH remains unclear, particularly since we ascertained biomarkers at a single timepoint among otherwise relatively young, healthy individuals. Future studies
should focus on serial measurements to examine whether
biomarkers may be useful in detecting dynamic subclinical cardiovascular remodelling as a potential screening
strategy. We acknowledge that, despite a multicentre
effort, our sample size is modest, and may preclude
detection of smaller effect sizes. Based on prior studies
on subjects with coronary artery disease,16 we ascertained
biomarkers immediately after peak exercise, and again
4 hours after maximal stress testing. It is possible that
Ho JE, et al. Open Heart 2017;4:e000615. doi:10.1136/openhrt-2017-000615

provoked changes with exercise might be better captured
during recovery or later following exercise. Furthermore,
it is possible that sustained, submaximal exercise, rather
than maximal, symptom-limited exercise may be a more
appropriate physiological stress to detect abnormalities
in cardiac biomarker release.45
In sum, we showed that dynamic exercise testing exaggerated resting differences in natriuretic peptides and
troponin elevations among individuals with overt HCM
compared with controls. It is important to note that
while we observed changes in NT-proBNP and hsTnI
with exercise in overt HCM, the clinical implications of
this finding remain unknown. The benefits of aerobic
exercise in the general population are well-known, and
whether this can be extended to patients with overt HCM
is an active area of investigation.46 Despite the presence
of altered cardiac structure and function by imaging, we
found no differences in biomarker profiles of cardiovascular stress and fibrosis among preclinical mutation
carriers without LVH compared with controls even after
maximal exercise provocation. Our findings highlight
that much remains to be elucidated with regard to the
early phenotypes of sarcomeric gene mutations and the
evolution of HCM. Continued investigation to identify
pathways involved early in the disease processes, as well
as serum biomarkers that reliably reflect their alteration,
will yield valuable insights with regard to characterising
disease development and targeting early preventive strategies to at-risk individuals.
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